TARGIT - IORT

Intrabeam TARGIT IORT is targeted intraoperative radiotherapy treatment for breast cancer. Conceived in the UK more than 20 years ago, thoroughly tested in clinical trials, TARGIT IORT treatment is widely used to treat breast cancer patients across the world.

​

“The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment [lumpectomy and radiation therapy] at the time of her operation, with lower toxicity.”  Lancet 2014;383:603-613

​

Please visit the dedicated website for TARGIT-IORT

Special relevance of TARGIT-IORT during the COVID-19 pandemic

 

TARGIT-IORT is given as a single dose during the cancer operation - so in most patients no visits to the radiotherapy department are required. This is especially relevant during the COVID-19 pandemic. When the radiotherapy is completed during the cancer operation, under the same anaesthetic, it greatly reduces the need for repeated post-operative visits to the hospital for postoperative external beam radiotherapy which are necessary for regimens such as IMPORT-Low or Fast-Forward which irradiates the whole breast.

​

This is why it has been included in several national and international guidelines for treatment of breast cancer during the COVID-19 pandemic caused by the widespread infection with the SARS-CoV-2 virus

​

During the COVID-19 pandemic, new guidelines for treatment of beast cancer  and radiotherapy have recommend using TARGIT-IORT because it would save patients the daily travel (and viral exposure) to radiotherapy departments:

​

Global radiation oncology's targeted preparedness for COVID-19  

https://www.sciencedirect.com/science/article/pii/S2405630820300227 

“where the technology is available the use of IORT may obviate the need for any further outpatient treatment and should be considered an option ..” 

 

British Association of Cancer Surgery (BASO~ACS) https://baso.org.uk/media/98159/covid_19_and_breast_cancer_march_2020.pdf

​

German University Hospitals 

https://ro-journal.biomedcentral.com/articles/10.1186/s13014-020-01527-1

​

Italian Association of Radiotherapy and Clinical Oncology

https://www.thegreenjournal.com/article/S0167-8140(20)30221-8/fulltext

​

China is increasing its use of TARGIT-IORT #breastcancer by equipping more centres with the TARGIT-IORT equipment 

 

 

Click here to see the national and international guidelines recommending TARGIT-IORT for breast cancer

Information about Intrabeam TARGIT IORT

How was TARGIT IORT for breast cancer developed?

  • The TARGIT technique uses the Intrabeam device for delivering precise and timely dose of intraoperative radiotherapy accurately to the tumour bed.
  • An academic insight led to the development of this device through a collaborative effort between University College London and the Photoelectron Corporation in 1990s.
  • It was first used on 2 July 1998 in the Middlesex Hospital, UCL, London. Intrabeam is currently manufactured by Carl Zeiss
  • The Intrabeam TARGIT IORT method has been rigorously tested in the ransomised TARGIT-A trial in which 3451 patients from 33 centres in 11 countries participated. Intrabeam TARGIT IORT given during the cancer operation was compared with the traditional radiation therapy given daily over several weeks after the operation.
  • Currently, breast cancer centres in over 300 hospitals in 38 countries offer Intrabeam TARGIT IORT to suitable patients



What was done in the TARGIT-A trial?

  • The TARGIT-A trial was a randomised trial testing an individualised approach of radiation after lumpectomy for breast cancer.
  • The comparison in the TARGIT-A trial was between standard radiation therapy that is given over several weeks after a lumpectomy vs. a risk-adapted approach using single dose of TARGeted Intraoperative radioTherapy (TARGIT) using Intrabeam given at the time of lumpectomy.
  • The risk-adapted protocol recommended that if the patients who had received TARGIT IORT with Intrabeam were found to have high risk factors postoperatively, they also received whole breast radiation – which occurred in 15-20% of cases as expected in the protocol; otherwise, about 80% of such patients completed their treatment (surgery and radiation) during their lumpectomy.
  • The pre-specified non-inferiority margin was an absolute difference in local recurrence of breast cancer between TARGIT and EBRT of 2.5% — in simple terms, if the absolute difference in local recurrence between the two treatments being compared was less than 2.5%, they would be considered non-inferior to each other in terms of local control of breast cancer. Patient preference studies have suggests majority of patients consider such a 2.5% margin as appropriate.
  • 3451 patients from 33 centres in 11 countries participated in the TARGIT-A trial (UK, USA, Germany, Italy, France Poland , Switzerland, Norway, Denmark, Canada and Australia) from 24 March 2000 to 25 June 2012. ( map).



How is TARGIT IORT given during surgery?

TARGIT IORT is given using the Intrabeam device. It is given during your surgery, while you remain asleep, under general anaesthetic. It adds about 30 minutes to the operation. It allows your specialist to deliver a focused dose of radiotherapy into the space where the breast cancer had been. This means that the radiotherapy is accurately targeted within the breast. This method avoids the potential damage to the skin, heart and lungs from traditional radiotherapy. You do not feel any effects from the radiotherapy and there are no additional scars on your breast. The surgical technique of Intrabeam TARGIT IORT, simplified: The surgeon removes the cancerous lump from the breast. The cancer and some surrounding normal tissue - the margin - is removed, leaving a small space called the tumour bed. A ball-shaped radiation small applicator is positioned precisely within the breast cavity, at the site of tumour, using meticulously placed sutures. Intrabeam TARGIT IORT is given as focused dose of targeted intraoperative radiotherapy into the breast, avoiding damage to the skin, heart and lungs.This takes about 30 minutes The breast wound and skin is surgically closed as usual.



Is Intrabeam TARGIT IORT Effective?

TARGIT IORT has been extensively tested in clinical trials over the past 20 years. The TARGIT-A trial, included 3451 patients treated in 33 hospitals in UK, Europe, USA and Australia and this trial compared TARGIT IORT with traditional radiotherapy. TARGIT IORT is given using the Intrabeam device. TARGIT IORT has only minimal side effects and they are fewer compared with traditional radiotherapy and the cosmetic outcome is similar to or better. The five-year results showed that when TARGIT is given at the same time as lumpectomy, the local-recurrence-free-survival is similar to traditional radiotherapy: 93.9% with TARGIT vs. 92.5% with traditional EBRT. As with all breast cancer treatments there is some uncertainty about the exact difference in local recurrence after TARGIT IORT compared with traditional radiotherapy. However, the UK National Institute of Care and Excellence have determined that such difference is very small (1 to 2%) and have recommended it for suitable patients in the NHS in hospitals that have the expertise and equipment.



Which patients could have taken part in the TARGIT-A trial

Women who were 45 or older with invasive ductal type cancer suitable for breast conservation (tumour size up to 3.5cm) were eligible to receive TARGIT IORT vs EBRT in the TARGIT-A trial. 3345 patients participated in TARGIT trial from 2000 to 2012, in 11 countries. ​ Click here for a web - tool to check suitability for Intrabeam TARGIT IORT



TARGIT-A Trial Design

In the randomised TARGIT-A trial, two policies of local radiation treatment are compared:



Design of the two parallel trials of immediate and delayed TARGIT-IORT

Before the primary surgery (Prepathology randomisation) This is the original method of entry into the TARGIT-A trial for a breast cancer patient. Once the decision to do a wide local excision (lumpectomy) is taken, and informed consent obtained, the randomisation takes place before surgery and if randomised to TARGIT, it is delivered to the fresh tumour bed immediately after lumpectomy for breast cancer. If at the postoperative pathology review, it is felt that they have a particularly high risk of local recurrence especially in other quadrants ( EIC, invasive lobular carcinoma or positive excision margins) then external beam radiotherapy can be added- all as part of the experimental arm of the trial. Centres could pre-specify additional such factors such as extensive lymphovascular invasion, multiple positive nodes, etc. After the primary surgery (Postpathology randomisation) ​ This mode of entry into the trial was added to enable patients in whom the excision of the cancer had already been performed. This was logistically easier in some centres and theoretically allowed better case selection – although it required a second procedure to be performed. Randomisation in the Targit-A trial is performed after the the primary cancer is removed and if allocated to receive TARGIT, single session intraoperative radiotherapy is given as a day-case operation.



What was found? Results of the TARGIT-A trial

  • When TARGIT is given with lumpectomy, the 5-year local recurrence of breast cancer is similar to EBRT
  • When TARGIT is given as a second procedure, the difference in local recurrence between TARGIT and EBRT was more than 2.5%
  • Breast cancer mortality with TARGIT were similar to EBRT
  • Mortality from other causes was significantly lower with TARGIT due to fewer deaths from cardiovascular causes and other cancers.
  • The results remain stable with longer follow up. The results were the same for the large number (1222) patients who were treated between 2000-2008 and had a median follow up of 5 years.



Some scientific publications related TARGIT-A trial

The TARGIT trial office has received its main funding from the Health Technology Assessment programme of the National Institutes of Health Research, Department of Health, UK for the TARGIT-A and TARGIT-B trials Futher details are at https://targit.org.uk ​ First publication of the main results (2010) ​ Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sutterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. The Lancet. 2010 ;376(9735):91-102. ​ 5-year results and first analysis of survival (2014) ​ Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HMR, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet. 11 November 2013.doi:10.1016/s0140-6736(13)61950-9 Full text PDF Podcast Full final 226 page report of the TARGIT-A trial for the the National Institutes of Health Research, Department of Health, UK (2016) Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Saunders C, Brew-Graves C, Potyka I, Morris S, Vaidya HJ, Williams NR, Baum M. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment 2016;20(73) TARGIT-A randomised clinical trial of TARGIT IORT using Intrabeam



Intrabeam TARGIT IORT for breast cancer is clinically effective - confirmed in the TARGIT-A international clinical trial

First publication of the main results (2010)​

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. 

The Lancet.  2010 ;376(9735):91-102.

​

5-year results and first analysis of survival (2014)​

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. 

The Lancet. 11 November 2013. doi:10.1016/s0140-6736(13)61950-9 

Full text PDF  Podcast

​

Full 226 page report of the TARGIT-A trial of Intrabeam TARGIT IORT for HTA, NIHR, Department of Health, UK (2016)

An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). 

Health Technology Assessment 2016;20(73)

​

Long term outcomes of the TARGIT-A trial (2020)

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m2836 (Published 19 August 2020)

​

Recent peer reviewed publications are below: more are available here

The TARGIT-A trial of intraoperative radiotherapy for breast cancer

How was TARGIT IORT for breast cancer developed?

  • The TARGIT technique uses the Intrabeam device for delivering precise and timely dose of intraoperative radiotherapy accurately to the tumour bed.
  • An academic insight led to the development of this device through a collaborative effort between University College London and the Photoelectron Corporation in 1990s.
  • It was first used on 2 July 1998 in the Middlesex Hospital, UCL, London. Intrabeam is currently manufactured by Carl Zeiss
  • The Intrabeam TARGIT IORT method has been rigorously tested in the ransomised TARGIT-A trial in which 3451 patients from 33 centres in 11 countries participated. Intrabeam TARGIT IORT given during the cancer operation was compared with the traditional radiation therapy given daily over several weeks after the operation.
  • Currently, breast cancer centres in over 300 hospitals in 38 countries offer Intrabeam TARGIT IORT to suitable patients



What was done in the TARGIT-A trial?

  • The TARGIT-A trial was a randomised trial testing an individualised approach of radiation after lumpectomy for breast cancer.
  • The comparison in the TARGIT-A trial was between standard radiation therapy that is given over several weeks after a lumpectomy vs. a risk-adapted approach using single dose of TARGeted Intraoperative radioTherapy (TARGIT) using Intrabeam given at the time of lumpectomy.
  • The risk-adapted protocol recommended that if the patients who had received TARGIT IORT with Intrabeam were found to have high risk factors postoperatively, they also received whole breast radiation – which occurred in 15-20% of cases as expected in the protocol; otherwise, about 80% of such patients completed their treatment (surgery and radiation) during their lumpectomy.
  • The pre-specified non-inferiority margin was an absolute difference in local recurrence of breast cancer between TARGIT and EBRT of 2.5% — in simple terms, if the absolute difference in local recurrence between the two treatments being compared was less than 2.5%, they would be considered non-inferior to each other in terms of local control of breast cancer. Patient preference studies have suggests majority of patients consider such a 2.5% margin as appropriate.
  • 3451 patients from 33 centres in 11 countries participated in the TARGIT-A trial (UK, USA, Germany, Italy, France Poland , Switzerland, Norway, Denmark, Canada and Australia) from 24 March 2000 to 25 June 2012. ( map).



How is TARGIT IORT given during surgery?

TARGIT IORT is given using the Intrabeam device. It is given during your surgery, while you remain asleep, under general anaesthetic. It adds about 30 minutes to the operation. It allows your specialist to deliver a focused dose of radiotherapy into the space where the breast cancer had been. This means that the radiotherapy is accurately targeted within the breast. This method avoids the potential damage to the skin, heart and lungs from traditional radiotherapy. You do not feel any effects from the radiotherapy and there are no additional scars on your breast. The surgical technique of Intrabeam TARGIT IORT, simplified: The surgeon removes the cancerous lump from the breast. The cancer and some surrounding normal tissue - the margin - is removed, leaving a small space called the tumour bed. A ball-shaped radiation small applicator is positioned precisely within the breast cavity, at the site of tumour, using meticulously placed sutures. Intrabeam TARGIT IORT is given as focused dose of targeted intraoperative radiotherapy into the breast, avoiding damage to the skin, heart and lungs.This takes about 30 minutes The breast wound and skin is surgically closed as usual.



Is Intrabeam TARGIT IORT Effective?

TARGIT IORT has been extensively tested in clinical trials over the past 20 years. The TARGIT-A trial, included 3451 patients treated in 33 hospitals in UK, Europe, USA and Australia and this trial compared TARGIT IORT with traditional radiotherapy. TARGIT IORT is given using the Intrabeam device. TARGIT IORT has only minimal side effects and they are fewer compared with traditional radiotherapy and the cosmetic outcome is similar to or better. The five-year results showed that when TARGIT is given at the same time as lumpectomy, the local-recurrence-free-survival is similar to traditional radiotherapy: 93.9% with TARGIT vs. 92.5% with traditional EBRT. As with all breast cancer treatments there is some uncertainty about the exact difference in local recurrence after TARGIT IORT compared with traditional radiotherapy. However, the UK National Institute of Care and Excellence have determined that such difference is very small (1 to 2%) and have recommended it for suitable patients in the NHS in hospitals that have the expertise and equipment.



Which patients could have taken part in the TARGIT-A trial

Women who were 45 or older with invasive ductal type cancer suitable for breast conservation (tumour size up to 3.5cm) were eligible to receive TARGIT IORT vs EBRT in the TARGIT-A trial. 3345 patients participated in TARGIT trial from 2000 to 2012, in 11 countries. ​ Click here for a web - tool to check suitability for Intrabeam TARGIT IORT



TARGIT-A Trial Design

In the randomised TARGIT-A trial, two policies of local radiation treatment are compared:



Design of the two parallel trials of immediate and delayed TARGIT-IORT

Before the primary surgery (Prepathology randomisation) This is the original method of entry into the TARGIT-A trial for a breast cancer patient. Once the decision to do a wide local excision (lumpectomy) is taken, and informed consent obtained, the randomisation takes place before surgery and if randomised to TARGIT, it is delivered to the fresh tumour bed immediately after lumpectomy for breast cancer. If at the postoperative pathology review, it is felt that they have a particularly high risk of local recurrence especially in other quadrants ( EIC, invasive lobular carcinoma or positive excision margins) then external beam radiotherapy can be added- all as part of the experimental arm of the trial. Centres could pre-specify additional such factors such as extensive lymphovascular invasion, multiple positive nodes, etc. After the primary surgery (Postpathology randomisation) ​ This mode of entry into the trial was added to enable patients in whom the excision of the cancer had already been performed. This was logistically easier in some centres and theoretically allowed better case selection – although it required a second procedure to be performed. Randomisation in the Targit-A trial is performed after the the primary cancer is removed and if allocated to receive TARGIT, single session intraoperative radiotherapy is given as a day-case operation.



What was found? Results of the TARGIT-A trial

  • When TARGIT is given with lumpectomy, the 5-year local recurrence of breast cancer is similar to EBRT
  • When TARGIT is given as a second procedure, the difference in local recurrence between TARGIT and EBRT was more than 2.5%
  • Breast cancer mortality with TARGIT were similar to EBRT
  • Mortality from other causes was significantly lower with TARGIT due to fewer deaths from cardiovascular causes and other cancers.
  • The results remain stable with longer follow up. The results were the same for the large number (1222) patients who were treated between 2000-2008 and had a median follow up of 5 years.



Some scientific publications related TARGIT-A trial

The TARGIT trial office has received its main funding from the Health Technology Assessment programme of the National Institutes of Health Research, Department of Health, UK for the TARGIT-A and TARGIT-B trials Futher details are at https://targit.org.uk ​ First publication of the main results (2010) ​ Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sutterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. The Lancet. 2010 ;376(9735):91-102. ​ 5-year results and first analysis of survival (2014) ​ Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HMR, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet. 11 November 2013.doi:10.1016/s0140-6736(13)61950-9 Full text PDF Podcast Full final 226 page report of the TARGIT-A trial for the the National Institutes of Health Research, Department of Health, UK (2016) Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Saunders C, Brew-Graves C, Potyka I, Morris S, Vaidya HJ, Williams NR, Baum M. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). Health Technology Assessment 2016;20(73) TARGIT-A randomised clinical trial of TARGIT IORT using Intrabeam



A bibliography of TARGIT-IORT for breast cancer

King Edward VII's Consulting Rooms

Prof Vaidya's Breast Clinic timings:

 

Thursdays 9.30 am to 1pm

Other days by appointment

​

Secretary: Shona Brogan

L: 02070348890 M: 07306 444 066

contact@londonbreastcancer.com

King Edward the VII's Hospital,

Emmanuel Kaye House
37 Devonshire St, Marylebone,

London, W1G 6QA

​

The London Clinic

20 Devonshire Place

London W1G 6BW

​